IDYA
6:00 AM
Catalyst Calendar
Mon, Sep 28, 2026
1 updatesFri, Sep 25, 2026
1 updatesWed, Sep 9, 2026
1 updatesIDYA
6:00 AM
IDEAYA Biosciences and Servier Announce First Patient Dosed in OptimUM-11 Global Phase 3 Registrational Trial of Darovasertib and Crizotinib as Adjuvant Therapy for Subjects with Uveal Melanoma
Trial Start • Phase 3Trial initiation Wed, Sep 9, 2026ideayabio.com
Tue, Sep 1, 2026
1 updatesMon, Aug 31, 2026
1 updatesIDYA
6:00 AM
IDEAYA Biosciences Announces Successful FDA Type C Meeting for IDE849, DLL3 TOP1 ADC, on Phase 3 Registrational Trial Design for Potential Accelerated and Full Approval in Extensive Stage Small Cell Lung Cancer
Presentation / Abstract • Phase 1/2ESMO 2026 presentation Thu, Oct 1, 2026ideayabio.com
Fri, Aug 28, 2026
1 updatesWed, Aug 19, 2026
1 updatesTue, Aug 4, 2026
1 updatesIDYA
6:00 AM
IDEAYA Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Update
Presentation / Abstract • Phase 2ESMO presentation Thu, Oct 1, 2026ideayabio.com
Fri, Jul 31, 2026
1 updatesMon, Jul 27, 2026
1 updatesIDYA
6:00 AM
IDEAYA Biosciences Announces IDE892, a Potential Best-in-Class MTA-Cooperative PRMT5 Inhibitor, Initiates Part 2 Monotherapy Expansion in the Phase 1/2 Study in MTAP-Deleted Pancreatic and Lung Cancers
Trial Design Update • Phase 1/2Trial update Mon, Jul 27, 2026ideayabio.com
Fri, Jul 17, 2026
1 updatesIDYA
9:00 AM
IDEAYA Biosciences Announces ESMO 2026 Presentations for Darovasertib and IDE849 Clinical Programs
Presentation / Abstract • Phase 2ESMO poster presentations Fri, Oct 23, 2026ideayabio.com